Pieris Pharmaceuticals Inc Stock OTC Bulletin Board
Equities
PIRS
US7207951036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
Apr. 19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Sales 2022 | 25.9M 0 | Sales 2023 | 42.81M 0 | Capitalization | 17.99M 0 |
---|---|---|---|---|---|
Net income 2022 | -33M - | Net income 2023 | -24M - | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M 0 | Net cash position 2023 | 26.37M 0 | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.57% |
Latest transcript on Pieris Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 70 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
1st Jan change | Capi. | |
---|---|---|
-1.65% | 103B | |
+6.75% | 101B | |
+7.02% | 23.07B | |
-12.60% | 22.23B | |
-5.24% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- PIRS Stock
- PIRS Stock